Page 1207 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 1207

Index     1193


                      nedocromil, 355–356, 362t          pharmacology of, 124–129         Autonomic synapses, 93
                      preparations available, 362t       structure of, 125, 125f          Autonomic transmission, 103, 104t
                      preventive uses of, 360          Autacoids, renal, 259              Autoplex, 623
                      sympathomimetics, 349–352, 350f, 362t  Autoclaving, 901             Autoreceptors, 100, 102t
                        beta 2 -selective, 351         Autoimmune disorders, 996. See also specific   Autosomal dominant hypophosphatemia,
                        toxicities of, 351–352                 types                             787–788
                    Astrocytes, 368                    Autoimmune (type II) drug reactions,   Autosomal dominant polycystic kidney
                    AT 1 , 304                                 982–983, 999                      disease, 268
                    AT 2 , 304                         Autoimmunity, 984                  Autosomal recessive hypercholesterolemia
                    Atazanavir, 74, 87, 871t, 879–880  Autologous stem cell transplantation,     (ARH), 631
                    Atenolol, 164t, 165, 170t. See also        G-CSF for, 603–604         Avastin, 1065
                            b-receptor antagonist drugs  Autonomic failure, pure, 137, 155  AV nodal block, 234–236, 235f
                      angina pectoris treated with, 210t  Autonomic motor nerves, 90f     Axon, 368
                      hypertension treated with, 179t, 183,   Autonomic nervous system (ANS), 90–93  Azapropazone, 649
                            191t                         anatomy of, 90f, 90–93, 91f      Azathioprine
                      structure of, 163f                 enteric nervous system in, 91f, 91–92  antirheumatic actions of, 650
                    Atezolizumab, 992                    ergotropic, 100                    immunosuppressive uses of, 988
                    Atherogenesis                        functions of, 89                   inflammatory bowel disease treated with,
                      description of, 627                on immune function, 89                  1109–1110
                      nitric oxide prophylaxis against,   parasympathetic division of, 90f, 90–91  TPMT on metabolism of, 81
                            342–343, 343f                somatic division of, 89          Azelaic acid, 1078
                    Atherosclerosis, 209                 sympathetic division of, 90f, 90–91  Azilsartan, 189
                    Athetosis, 492, 505                  trophotropic, 100                Azithromycin, 820, 824t
                    Atomoxetine, 151                   Autonomic pharmacology, 89–106. See also   Azoles, 856–859, 861t
                    Atonic seizures, 430. See also Seizures    specific agents              adverse effects of, 857–858
                    Atorvastatin, 632–634, 639t          autonomic nervous system in, 90–93.   chemistry and pharmacokinetics of,
                    Atosiban                                   See also Autonomic nervous        856–857, 857f, 858t
                      description of, 681, 684t                system (ANS))                clinical uses of, 857–858
                      preterm labor managed with, 206    in eye, 105b, 105f                 dermatologic
                    Atovaquone, 919f, 926                functional organization of, 100–103  oral, 1073
                    Atovaquone-proguanil, 920t             cardiovascular function integration in,   topical, 1072
                    Atracurium. See also Neuromuscular         100, 102f                    drug interactions of, 857–858,
                            blocking drugs                 central integration in, 91f, 100, 101t,   1159t–1160t
                      pharmacokinetics of, 477                 103                          fluconazole, 857f, 858, 858t
                      properties of, 478t                  direct effects on organ systems of,   itraconazole, 857f, 858, 858t, 861t
                      structure of, 476f                       100, 101t                    ketoconazole, 857f, 858, 858t, 861t
                    Atrial fibrillation                    postsynaptic regulation in, 103, 103f  mechanisms of action and resistance to,
                      antiarrhythmic agents for, 249b      presynaptic regulation in, 100, 102t,   857
                      electrocardiogram of, 236f               103                          posaconazole, 858t, 859
                      with left ventricular dysfunction, 228,   functions of, 89–90         preparations available, 862t
                            253                          neurotransmitter chemistry in, 90f,   topical, 860–861
                    Atrial flutter, ECG of, 236f               93–98                        voriconazole, 857f, 858t, 858–859
                    Atrial natriuretic peptide (ANP)       adrenergic transmission in, 95–97,   Azo reductions, 61t
                      description of, 34, 308–309, 309f        96f–97f                    Aztreonam, 806, 812t
                      on kidney, 259                       cholinergic and noradrenergic fibers
                      mechanism of action of, 28               in, 90f, 93                B
                    Atrioventricular (AV) node, 228, 229f  cholinergic transmission in, 93–95,   B 1  receptor antagonists, 307
                    Atropine, 124–129, 130t. See also          94f                        B 2  receptor agonists, 308
                            Muscarinic receptor blockers   cotransmitters in, 93          B 2  receptor antagonists, 307–308
                      actions of, 353                      cotransmitters in cholinergic and   Babesiosis, 924
                      chemistry and pharmacokinetics in, 125,   adrenergic nerves in, 97–98  Bacillus subtilis, 811
                            125f                         nonadrenergic, noncholinergic neurons   Bacitracin, 811, 1070
                      cholinergic poisoning treated with, 132  in, 91f, 97                Baclofen
                      clinical pharmacology of, 130–133  pharmacologic modification of      for dependence and addiction, 588
                      discovery of, 353                        autonomic function in, 103,   spasmolytic actions of, 485–487, 486f,
                      elimination of, 125                      104t, 105                         489t
                      intoxication with, 119             receptors in, 98–99, 99t         Bacterial cell wall, penicillins on, 797, 797f
                      pharmacodynamics of, 125–129     Autonomic receptors, 98–99, 99t    Bacterial food poisoning, 1034
   1202   1203   1204   1205   1206   1207   1208   1209   1210   1211   1212